Lyell Immunopharma, Inc. SEC filings LYEL
Lyell Immunopharma, Inc. has 359 filings in SEC EDGAR's recent list, going back to Mar 20, 2020. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Nov 4, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 15, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 12, 2026 | Mar 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 9, 2026 | Mar 6, 2026 |
| 8-K |
Current report
Other events
|
Dec 8, 2025 | Dec 7, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Dec 5, 2025 | Dec 3, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Nov 10, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Officer or director change
|
Nov 3, 2025 | Oct 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 16, 2025 | Sep 15, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 25, 2025 | Jul 24, 2025 |
| 8-K |
Current report
Unregistered share sale
|
Jun 26, 2025 | Jun 20, 2025 |
| 8-K |
Current report
Other events
|
Jun 17, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 9, 2025 | Jun 9, 2025 |
| 8-K |
Current report
Change to shareholder rights
|
May 28, 2025 | May 27, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 21, 2025 | May 15, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Regulation FD disclosure
|
Apr 1, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 11, 2025 | Mar 11, 2025 |
| 8-K |
Current report
Listing notice
|
Jan 24, 2025 | Jan 23, 2025 |
| 8-K/A | Amended current report | Jan 10, 2025 | Oct 31, 2024 |
| 8-K |
Current report
Other events
|
Dec 10, 2024 | Dec 9, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 26, 2024 | Nov 22, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Officer or director change, Regulation FD disclosure
|
Oct 31, 2024 | Oct 31, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
Oct 24, 2024 | Oct 24, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2024 | Aug 7, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 26, 2024 | Jun 26, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2024 | Jun 14, 2024 |
| 8-K |
Current report
Results of operations
|
May 6, 2024 | May 6, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 28, 2024 | Feb 28, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 20, 2023 | Nov 16, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2023 | Nov 7, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2023 | Sep 11, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2023 | Jun 16, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 6, 2023 | Jun 1, 2023 |
| 8-K |
Current report
Results of operations
|
May 4, 2023 | May 4, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 28, 2023 | Feb 28, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 16, 2022 | Dec 14, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2022 | Nov 8, 2022 |
| 8-K |
Current report
Agreement ended
|
Oct 24, 2022 | Oct 24, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 6, 2022 | Oct 6, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2022 | Aug 4, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Results of operations
|
May 10, 2022 | May 10, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2022 | Mar 29, 2022 |
| 8-K |
Current report
Officer or director change
|
Feb 15, 2022 | Feb 11, 2022 |
| 8-K |
Current report
Material agreement, Other events
|
Dec 17, 2021 | Dec 15, 2021 |
| 8-K |
Current report
Other events
|
Dec 3, 2021 | Dec 2, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 12, 2021 |
| 8-K |
Current report
Officer or director change
|
Oct 28, 2021 | Oct 23, 2021 |
| 8-K/A |
Amended current report
Officer or director change
|
Oct 1, 2021 | Sep 29, 2021 |
| 8-K |
Current report
Officer or director change
|
Sep 30, 2021 | Sep 29, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2021 | Aug 12, 2021 |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LYEL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1806952
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.